Alivus Life Sciences Board Meeting Scheduled to Approve Unaudited Financial Results

Alivus Life Sciences has announced a board meeting on November 06, 2025, to review and approve the unaudited financial results for the quarter and half-year ending September 30, 2025. The company has also announced the closure of the Trading Window for designated persons from September 30, 2025, to November 08, 2025, inclusive, in connection with this board meeting.

Board Meeting Announcement

Alivus Life Sciences is set to hold a meeting of its Board of Directors on November 06, 2025. The primary agenda of this meeting is to consider and approve the unaudited financial results for the quarter and half-year that concluded on September 30, 2025.

Trading Window Closure

In line with company policy, Alivus Life Sciences has announced the closure of its trading window. This restriction applies to the company’s designated persons and will be in effect from September 30, 2025, until November 08, 2025. The closure is directly linked to the impending approval of the unaudited financial results for the period ending September 30, 2025.

Source: BSE

InvestyWise News
InvestyWise News
Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!